全文获取类型
收费全文 | 135685篇 |
免费 | 13279篇 |
国内免费 | 4325篇 |
专业分类
耳鼻咽喉 | 883篇 |
儿科学 | 2336篇 |
妇产科学 | 1527篇 |
基础医学 | 27967篇 |
口腔科学 | 3262篇 |
临床医学 | 9101篇 |
内科学 | 21148篇 |
皮肤病学 | 2766篇 |
神经病学 | 12375篇 |
特种医学 | 3159篇 |
外国民族医学 | 39篇 |
外科学 | 11008篇 |
综合类 | 14421篇 |
现状与发展 | 19篇 |
预防医学 | 5570篇 |
眼科学 | 1419篇 |
药学 | 18677篇 |
35篇 | |
中国医学 | 4544篇 |
肿瘤学 | 13033篇 |
出版年
2024年 | 350篇 |
2023年 | 2225篇 |
2022年 | 4943篇 |
2021年 | 5720篇 |
2020年 | 4895篇 |
2019年 | 5209篇 |
2018年 | 5031篇 |
2017年 | 4973篇 |
2016年 | 4775篇 |
2015年 | 5529篇 |
2014年 | 7954篇 |
2013年 | 8485篇 |
2012年 | 7335篇 |
2011年 | 9043篇 |
2010年 | 7382篇 |
2009年 | 7556篇 |
2008年 | 7326篇 |
2007年 | 6490篇 |
2006年 | 5692篇 |
2005年 | 5196篇 |
2004年 | 4505篇 |
2003年 | 3975篇 |
2002年 | 3057篇 |
2001年 | 2547篇 |
2000年 | 2142篇 |
1999年 | 1970篇 |
1998年 | 1861篇 |
1997年 | 1712篇 |
1996年 | 1602篇 |
1995年 | 1496篇 |
1994年 | 1320篇 |
1993年 | 1183篇 |
1992年 | 897篇 |
1991年 | 810篇 |
1990年 | 656篇 |
1989年 | 543篇 |
1988年 | 500篇 |
1987年 | 493篇 |
1986年 | 590篇 |
1985年 | 818篇 |
1984年 | 787篇 |
1983年 | 615篇 |
1982年 | 612篇 |
1981年 | 516篇 |
1980年 | 460篇 |
1979年 | 403篇 |
1978年 | 248篇 |
1977年 | 203篇 |
1976年 | 213篇 |
1975年 | 137篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
11.
12.
《Clinical Lymphoma, Myeloma & Leukemia》2022,22(8):608-617
BackgroundConsiderable progress has been made in therapeutic options for multiple myeloma (MM). Understanding the current landscape of MM treatment options and associated outcomes in the real world is important in providing key insights into clinical and knowledge gaps which could be targeted for further optimization.MethodsThe Canadian Myeloma Research Group Database (CMRG-DB) is a prospectively maintained disease-specific database with >7000 patients. The objective of this study was to describe the trends in the treatment landscape and outcomes including early mortality, time to next treatment, and overall survival (OS) in each line of treatment stratified by autologous stem cell transplant (ASCT) receipt among newly-diagnosed MM patients in Canada between 2007 and 2018.ResultsA total of 5154 patients were identified among which 3030 patients (58.8%) received an upfront ASCT and 2124 (41.2%) did not. At diagnosis, the median age was 64 years and 58.6% were males. Bortezomib and lenalidomide were most frequently used (>50%) in first and second-line treatment respectively among both the ASCT and non-ASCT cohort. The median OS was 122.0 months (95% Cl 115.0-135.0 months) and 54.3 months (95% CI 50.8-58.8 months) for the ASCT and non-ASCT cohort respectively with an incremental decrease in OS in each subsequent line of treatment.ConclusionWe present the largest study to date in the Canadian landscape showing the characteristics, therapy usage, and outcomes among MM patients. This information will be critical in benchmarking current outcomes and provide key insight into areas of unmet needs and gaps for improvement of MM patients nationally. 相似文献
13.
14.
15.
Ling Zhang Xue-Jun Shang Hong-Fei Li Yu-Qin Shi Wei Li Maria E Teves Zhi-Qiong Wang Gao-Feng Jiang Shi-Zhen Song Zhi-Bing Zhang 《Asian journal of andrology》2015,17(1):86-93
Mammalian spermatogenesis is a well-organized process of cell development and differentiation. Meiosis expressed gene 1 (MEIG1) plays an essential role in the regulation of spermiogenesis. To explore potential mechanisms of MEIG1''s action, a yeast two-hybrid screen was conducted, and several potential binding partners were identified; one of them was membrane occupation and recognition nexus repeat containing 3 (MORN3). MORN3 mRNA is only abundant in mouse testis. In the testis, Morn3 mRNA is highly expressed in the spermiogenesis stage. Specific anti-MORN3 polyclonal antibody was generated against N-terminus of the full-length MORN3 protein, and MORN3 expression and localization was examined in vitro and in vivo. In transfected Chinese hamster ovary cells, the antibody specifically crossed-reacted the full-length MORN3 protein, and immunofluorescence staining revealed that MORN3 was localized throughout the cytoplasm. Among multiple mouse tissues, about 25 kDa protein, was identified only in the testis. The protein was highly expressed after day 20 of birth. Immunofluorescence staining on mixed testicular cells isolated from adult wild-type mice demonstrated that MORN3 was expressed in the acrosome in germ cells throughout spermiogenesis. The protein was also present in the manchette of elongating spermatids. The total MORN3 expression and acrosome localization were not changed in the Meig 1-deficient mice. However, its expression in manchette was dramatically reduced in the mutant mice. Our studies suggest that MORN3 is another regulator for spermatogenesis, probably together with MEIG1. 相似文献
16.
Melatonin induces apoptosis of colorectal cancer cells through HDAC4 nuclear import mediated by CaMKII inactivation 下载免费PDF全文
Melatonin induces apoptosis in many different cancer cell lines, including colorectal cancer. However, the precise mechanisms involved remain largely unresolved. In this study, we provide evidence to reveal a new mechanism by which melatonin induces apoptosis of colorectal cancer LoVo cells. Melatonin at pharmacological concentrations significantly suppressed cell proliferation and induced apoptosis in a dose‐dependent manner. The observed apoptosis was accompanied by the melatonin‐induced dephosphorylation and nuclear import of histone deacetylase 4 (HDAC4). Pretreatment with a HDAC4‐specific siRNA effectively attenuated the melatonin‐induced apoptosis, indicating that nuclear localization of HDAC4 is required for melatonin‐induced apoptosis. Moreover, constitutively active Ca2+/calmodulin‐dependent protein kinase II alpha (CaMKIIα) abrogated the melatonin‐induced HDAC4 nuclear import and apoptosis of LoVo cells. Furthermore, melatonin decreased H3 acetylation on bcl‐2 promoter, leading to a reduction of bcl‐2 expression, whereas constitutively active CaMKIIα(T286D) or HDAC4‐specific siRNA abrogated the effect of melatonin. In conclusion, the present study provides evidence that melatonin‐induced apoptosis in colorectal cancer LoVo cells largely depends on the nuclear import of HDAC4 and subsequent H3 deacetylation via the inactivation of CaMKIIα. 相似文献
17.
18.
Hend Kothayer Samy M. Ibrahim Moustafa K. Soltan Samar Rezq Shireen S. Mahmoud 《Drug development research》2019,80(3):343-352
In light of the pharmacophoric structural requirements for achieving anticonvulsant activity, a series of N-(1-methyl-4-oxo-2-un/substituted-1,2-dihydroquinazolin-3[4H]-yl)benzamide (4a-g) and N-(1-methyl-4-oxo-2-un/substituted-1,2-dihydroquinazolin-3[4H]-yl)-2-phenylacetamide (4h-n) derivatives were synthesized in two steps starting from the reaction of N-methyl isatoic anhydride with the appropriate hydrazide and followed by condensation with the appropriate aldehyde. The anticonvulsant activities of the synthesized compounds were evaluated according to the anticonvulsant drug development (ADD) programme protocol. Among the synthesized compounds, 4n showed promising activity in both the maximal electroshock (MES) and pentylenetetrazole (PTZ) tests with median effective dose (ED50) values of 40.7 and 6 mg/kg, respectively. The six most promising derivatives, 4b , 4a , 4c , 4f , 4j , and 4i , showed very low ED50 values in the PTZ test (3.1, 4.96, 8.68, 9.89, 12, and 13.53 mg/kg, respectively). All the tested compounds showed no to low neurotoxicity in the rotarod test with a wide therapeutic index. Docking studies of compound 4n suggested that GABAA binding could be the mechanism of action of these derivatives. The in silico drug likeliness parameters indicated that none of the designed compounds violate Lipinski's rule of five and that they are able to cross the blood–brain barrier.
相似文献
Hit, Lead & Candidate Discovery |
19.
20.